Take the first step to address patient cancer risk before they leave your office
Research indicates that as many as 40% of patients fail to adhere to their doctor’s treatment recommendations¹. Patients’ non-adherence to physician recommendations for cancer screenings puts lives in jeopardy since cancers found in later stages are harder to cure.
MyCancerRisk™ is a program offered by Innovative Diagnostic Laboratory to help improve patient adherence to cancer screening through convenient blood-based, cancer risk assessment tests that can be performed at the same time as a routine blood draw. Unlike other tests that identify cancer in its later stages, our tests can help identify early cancer indicators that give physicians the information they need to encourage patients to comply with national screening guidelines. Test results come with educational materials to help create teachable moments between physicians and patients.
Our three step program helps physicians:
1. Identify a patient’s individual cancer risk through convenient blood-based tests you can initiate right in your own office.
2. Communicate the results to patients and help them understand their individual risk for certain types of cancers.
3. Address patient risk by encouraging further screenings & the adoption of healthier habits.
How do I get started?
When you enroll with IDL’s MyCancerRisk program you’ll receive everything you need to succeed:
- Brochures, posters and online information for patients to learn more about their individual cancer risk and information to encourage dialogue between you and your patients
- Easy ordering of test supplies for your practice
- Training and ongoing education on test results
ColonSentry® can help you decide if further diagnostic procedures are needed
The ColonSentry test measures the expression of 7 gene biomarkers that are indicators of colorectal cancer. The ColonSentry® blood test can be incorporated into a routine blood draw to encourage at risk patients to be screened for colorectal cancer.
When a lecture isn’t enough, EarlyCDT® Lung may spark a change for high risk patients
EarlyCDT®-Lung measures seven autoantibodies in the blood that serve as early indicators of lung cancer. EarlyCDT®-Lung can help physicians assess high risk, asymptomatic patients and can help detect lung cancers before they are visible by CT.2,3,4
phi has been demonstrated to have higher specificity than PSA and % free PSA alone
phi is a blood test that is up to 3 times more specific in detecting prostate cancer than PSA and percent free PSA alone. phi can help differentiate prostate cancer from benign conditions and therefore reduce unnecessary biopsies. *5,6
1. The challenge of patient adherence: Ther Clin Risk Manag. 2005 Sep; 1(3): 189–199.
Leslie R Martin, Summer L Williams. Kelly B Haskard, and M Robin DiMatteo
2. Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol 2011;22:383-389.
3. Lam S, Boyle P, Healey GF, Maddison P, Peek L, et al. EarlyCDT-Lung: An immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res 2011;4(7):1126-34.
4. Chapman CJ, Healey GF, Murray A, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol 2012;33(5):1319-26. 5 IDL-210
5. Urol. 2015 April ; 193(4): 1163–1169. doi:10.1016/j.juro.2014.10.121.
6. Am J Clin Exp Urol 2014;2(4):343-350
* At 90 percent clinical sensitivity.